Mary B. Todd

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono et al. · European Urology · 2014 · 271 citations · Full text

Urology, Oncology, Abiraterone Acetate +7

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

Kim N., Andrew Protheroe, Gaetano Facchini et al. · The Lancet Oncology · 2018 · 163 citations

Patient-reported Outcomes, Urology, Genitourinary Cancer +8

Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma

Robert J. Motzer, Robert J. Amato, Mary B. Todd et al. · Investigational New Drugs · 2003 · 153 citations

Urology, Phase Ii Trial, Genitourinary Cancer +5

Prognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response Modifiers

Sridhar Mani, Mary B. Todd, Karol H. Katz et al. · The Journal of Urology · 1995 · 142 citations